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Background: The first phase of malaria infection occurs in the liver and is clinically silent. Inside hepatocytes each
Plasmodium sporozoite replicate into thousands of erythrocyte-infectious merozoites that when released into the
blood stream result in clinical symptoms of the disease. The time between sporozoite inoculation and the appearance
of parasites in the blood is defined as the pre-patent period, which is classically analysed by time-consuming and
labor-intensive techniques, such as microscopy and PCR.
Methods: Luciferase-expressing Plasmodium berghei parasites were used to measure pre-patent period of malaria
infection in rodents using a bioluminescence assay that requires only one microliter of blood collected from
the tail-vein. The accuracy and sensitivity of this new method was compared with conventional microscopy
and PCR based techniques, and its capacity to measure the impact of anti-malarial interventions against the
liver evaluated.
Results: The described method is very sensitive allowing the detection of parasites during the first cycles of
blood stage replication. It accurately translates differences in liver load due to inoculation of different
sporozoite doses as well as a result of treatment with different primaquine regimens.
Conclusions: A novel, simple, fast, and sensitive method to measure pre-patent period of malaria infection in
rodents is described here. The sensitivity and accuracy of this new method is comparable to standard PCR
and microscopy-based techniques, respectively.Background
Malaria infection is initiated when Plasmodium parasites
enter the host through the bite of an infected Anopheles
mosquito. The clinical manifestations of the disease
occur during the intra-erythrocytic stage of replication,
but prior to infecting red blood cells Plasmodium para-
sites go through an obligatory and asymptomatic phase
of intrahepatic development.
Upon reaching the liver, sporozoites invade host hepa-
tocytes inside which they develop into thousands of red
blood cell-infectious merozoites [1]. Targeting this asymp-
tomatic stage of infection is crucial for the success of anti-
malarial interventions since clearance of the parasite at this
stage completely abrogates the clinical manifestation and
transmission of the disease. As such, the development of* Correspondence: mmota@fm.ul.pt
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article, unless otherwise stated.anti-malarial vaccine candidates and chemoprophylaxis
approaches focused on the liver stage of infection is crit-
ical [2,3]. It is, however, challenging to evaluate the efficacy
of anti-malarial strategies that target the development of
Plasmodium parasites in the liver.
Rodent models are frequently used to study the impact
of the different strategies in vivo and several methods
have been developed to accurately measure Plasmodium
liver infection (for a comprehensive review see [4]). Never-
theless, standard methods are invasive and terminal, as they
require the collection of liver tissue to determine parasite
burden. Among the usual methods are the microscopy-
based techniques to analyse fixed livers upon immunofluor-
escence assay (IFA), using Plasmodium-specific antibodies,
or live samples using transgenic parasites engineered to
express fluorescent proteins [5] and quantitative reverse
transcriptase PCR (qRT-PCR) to detect Plasmodium-specific
targets, typically 18S ribosomal RNA, or trans-genesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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usually performed in the end phase of Plasmodium devel-
opment in the liver (between 40 and 48 hr after infection
with Plasmodium berghei or Plasmodium yoelii sporozo-
ites), and prior to the egress of parasites into the blood. As
such, they are inappropriate to evaluate the impact of the
anti-malarial strategies on the final stage of the parasite
maturation, egress from the liver and onset of the symp-
tomatic blood infection [7].
The length of the pre-patent period, i.e. the time be-
tween sporozoite inoculation and the appearance of par-
asites in the blood, directly reflects the duration of the
liver stage and the number of infective merozoites pro-
duced. However, determining the onset of blood parasit-
aemia through the analysis of blood smears by microscopy
is time-consuming and not accurate, as it may take a few
cycles of blood stage replication to achieve a detectable
level of parasites in the blood. The molecular methods
(PCR-based techniques) are more sensitive allowing not
only to accurately measure parasite load but also to deter-
mine speciation. They are, however, expensive and labor
intensive methods [8,9].
The recently developed chemiluminescent parasites
have become valuable tools in experimental malaria re-
search. The luciferase-expressing parasites can be used
to assess parasite hepatic development through non-
invasive methods and still allowing infection to proceed
to the blood stage in the same animals where liver bur-
den was previously assessed [10]. As such, it is possible,
using these parasites to evaluate the effect of specific
anti-malarial strategies that target the liver stage.
Here, a further use for these transgenic luciferase-
expressing lines is proposed to accurately evaluate the
pre-patent period of malaria infection. This new assay
constitutes a simple, fast, non-invasive, and highly sensi-
tive bioluminescent assay allowing a precise evaluation
of the malaria pre-patent period as it allows the detec-
tion of blood parasites as early as 60 hr after sporozoite
inoculation. This means that this method is able to de-
tect the first generation of merozoites released from the
liver, since that merozoite egress from hepatocytes starts
48 hr after infection with sporozoites [11].
Methods
Mice, parasites and reagents
Male C57BL/6 mice, aged six to eight weeks were pur-
chased from Charles River and housed in the pathogen-
free facilities of the Instituto de Medicina Molecular,
Lisbon (IMM). The luciferase expressing P. berghei ANKA
transgenic parasite lines (676m1cl1 line) was used in all
the experiments. Sporozoites were obtained by disrup-
tion of the salivary glands of freshly dissected infected
female Anopheles stephensi mosquitoes and collected
in DMEM (Dulbecco’s Modified Eagle Medium fromGIBCO). Mosquitoes were bred at the insectary facility of
the Instituto de Medicina Molecular. Firely luciferase
assay kit was purchased from Biotium, Hayward, USA and
DNA extraction kit was purchased from QIAGEN.
Ethics statement
All experimental procedures were performed according
to EU recommendations for good practices and animal
welfare and approved by the IMM Animal Care and
Ethical Committee (AEC_2010_024_MM_RDT_General_
IMM). Animals were monitored daily and every effort was
made to minimize suffering. Upon completion of experi-
ments, mice were euthanized via administration of CO2
followed by cervical dislocation.
Infection and bioluminescence assay
Plasmodium liver stage infection was established by
mosquito bite, through a 20 minutes bite of one infected
Anopheles mosquito, or intravenously (IV) through retro-
orbital injection of the designated quantity of sporozoites.
At the selected time-points 1 μL of blood was collected
from the tail vein into 50 μL of lysis buffer. Luminescence
was determined by adding 50 μL of D-luciferin dissolved
in firely luciferase assay buffer (according to the manufac-
turer’s instructions) to 30 μL of lysate and immediately
measured using a multiplate reader (Tecan, Switzerland).
Values of luciferase activity are expressed as relative lumi-
nescence units (RLU).
DNA extraction and real-time PCR analysis
At the selected time-points, and concomitant with the
sampling for bioluminescence assay, 1 μL of blood was
collected from the tail vein into 200 μL of 1× PBS. DNA
extraction was performed using the DNeasy Blood &
Tissue Kit, according to the manufacturer’s instructions.
Real-time PCR analysis to was performed using 2 μL of
DNA and the iTaq Universal SYBR Green Supermix
from Bio-Rad according to the manufacturer’s instruc-
tions. Expression levels of 18 s rRNA were normalized
against the housekeeping gene seryl-tRNA synthetase
(PbANKA_061540). Gene expression values were calcu-
lated based on the ΔΔCt method. Primer pairs used





Blood parasitaemia was monitored daily by light micros-
copy, starting 60 hr after infection. Air-dried thin blood
smears were fixed in absolute methanol and stained with
Giemsa. Percentage of infected red blood cells (iRBC)
was assessed by microscopic examination of 15 fields of
Giemsa-stained blood smears.
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Statistically significant differences between two different
groups were analysed using the Mann–Whitney test. P <
0.05 were considered statistically significant. Significances
are represented in the figures as follows *P < 0.05; **P <
0.01. All statistic tests were performed using Graph Prism
5.0 software.
Results
Bioluminescence assessment of blood parasite load
correlates with parasitaemia measurements
To determine if bioluminescence levels measured in
total blood correlate with the sporozoite inoculum used
to initiate infection, mice were infected with increasing
numbers of luciferase-expressing P. berghei sporozoitesFigure 1 Bioluminescence assessment of blood parasite load correlat
circulating parasites at 60 hr after infection. A: Bioluminescence measu
of luciferase-expressing P. berghei ANKA sporozoites (500, 5,000 or 50,000 in
bioluminescence assessment with blood-stage parasitaemia determined by b
P. berghei ANKA sporozoites. C: Assessment of pre-patent period at 60 h and
injected IV) and with or without primaquine treatment D: Assessment of pre-
infected mosquito. E: Comparison of bioluminescence measurement with qP
sporozoites. Non-infected (Ni) blood samples are included as control. (A-D: Ea
mean value. E: Each bar represents the bioluminescence signal of one infecte
technical duplicates).(500, 5,000 and 50,000). Four days later luciferase activ-
ity was measured using 1 μL of tail-vein blood. The re-
sults clearly show that bioluminescence is detected 4
days after sporozoite infection and that its level is pro-
portional to the number of sporozoites used to initiate
infection (Figure 1A). In addition, the administration of
primaquine (PRQ), clinically used to eliminate liver stage
parasites, resulted in a significant reduction in the bio-
luminescence measurements in total blood in a dose-
dependent manner, suggesting that the luminescence
levels detected in the blood are directly proportional to
the level of liver infection. Importantly, the biolumines-
cence measurements show a direct correlation with the
level of parasitaemia quantified by blood smear monitor-
ing (Figure 1B).es with parasitaemia measurements and quantitatively detects
rements in the blood four days after infection with different numbers
jected IV), with or without primaquine treatment. B: Correlation of
lood smear analysis at day 4 after infection with luciferase-expressing
72 h after infection with different number of sporozoites (500 or 50,000
patent period at 60 h and 72 h after infection transmitted by the bite of 1
CR analysis of parasite load at 48, 60 and 72 hr after infection with 50,000
ch dot represents the signal of one infected mouse. Bars represent the
d mouse measured in technical triplicates. PCR analysis was performed in
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parasites 60 hr upon infection with 50,000 sporozoites
Having shown that bioluminescence measurements have
a direct correlation with the number of circulating para-
sites, the next step was to establish the earliest time
point after sporozoite infection, as well as the lowest
level of parasites that this assay could detect. Infections
were initiated by IV injection of 500 and 50,000 sporozo-
ites and bioluminescence measurements from 1 μL of
tail-vein blood were performed 60 and 72 hr after infec-
tion. The results show that circulating parasites can be
quantified by this method as early as 60 hr when the in-
fection is initiated with 50,000 sporozoites (Figure 1C).
Importantly, the luminescence levels are proportionally
lower upon administration of primaquine (PRQ) on the
day of infection (estimated to reduce liver infection by
90%) or 24 hr after infection (estimated to reduced ap-
proximately 50% of liver parasite load). In addition, an
infection initiated by the bite of one single infected mos-
quito could be detected 72 hr after the infectious bite
(Figure 1D) in levels similarly to the inoculation IV of
500 sporozoites (Figure 1C).
Sensitivity of the bioluminescence assay is similar to the
PCR detection of blood parasite load
To further test the sensitivity of the assay, biolumines-
cence measurements were compared with real-time PCR
analysis, both in samples of 1 μL of tail-vein blood of an-
imals infected by IV injection of 50,000 sporozoites at
48, 60 and 72 hr after sporozoite infection. The results
show that the sensitivity of both methods is similar, as in
both cases the differences to non-infected (Ni) blood sam-
ples are only significant at 60 and 72 hr, but not at 48 hr
after infection. The results of the analysis of technical trip-
licates are further indicators of assay robustness.
Discussion and conclusions
The bioluminescent assay described here allows the fast
and efficient quantitative monitoring of pre-patent
period in a minimally invasive manner. This technique
has clear benefits over the traditional, time-consuming,
examination of blood smears to detect the presence of
circulating parasites. It takes a few cycles of blood stage
replication to produce a level of parasitaemia detectable
by blood smear analysis; as such, the measurement of
the pre-patent period by this method may be inaccurate
and may include the impact of the anti-malarial strategy
in the blood stage without providing a direct quantifica-
tion of production and release of infective first-generation
merozoites. Additionally, this assay presents similar sensi-
tivity to the widely used PCR-based methods.
The requirement to use the chemiluminescent parasites
further allows the combination with bioluminescence as-
says during liver stage infection to better discriminate theeffects of distinct intervention strategies. The recent re-
ports of luciferase-expressing parasites of different species,
including P. yoelii [12] as well as Plasmodium falciparum
[13], will allow the expansion of this protocol to these spe-
cies. Most importantly, the description of liver and blood-
humanized mice (until now still in separate hosts) [14,15]
may soon allow the establishment of this assay to test dif-
ferent strategies against P. falciparum infection. As such,
the use of different luciferase-expressing parasites may
greatly accelerate and streamline the process of identifying
and analysing future vaccine candidates as well as drug
candidates against the pre-erythrocytic stages of malaria
parasites, including those that may target the parasite at
very late states or transition period between stages.
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